Page 0005

NEWS

Study to improve

management of T1

and T2 diabetes

The Swedish health-tech company Brighter

has signed an agreement with the Northern

Care Alliance NHS Trust to set up a research

project to demonstrate the benefits of its

product Actiste in the management of T1 and

T2 diabetes.

The trust covers the greater Manchester

areas of Salford, Oldham, Rochdale and

Bury, and the data gathered from patients

in the region will be shared with the wider

patient community of people with diabetes,

researchers, front line care providers, health

insurers and other partners.

Actiste is described as the world's first

'unified diabetes care device' with a mobile

connection. Designed to simplify life for

people with insulin-treated diabetes, it

combines a blood sampler, blood glucose

meter and insulin pen with an app on a smart

device (such as a smart phone) for daily

record-keeping.

Blood glucose measurements and injected

insulin doses are automatically time stamped,

saved and synced with the companion app

which can also be used to set reminders,

specify blood glucose target ranges, and add

tags for physical activity, meals, mood and

other markers of overall health.

Brighter has already published the results

from a similar pilot project in Sweden and says

it is planning to continue conducting userexperience

projects and clinical research to

demonstrate how Actiste can address unmet

needs in the management of diabetes.

To read more CLICK HERE.

Nice Work

MIT App

A team led by mechanical engineers from the Massachusetts

Institute of Technology (MIT) in America has patented two new

devices to reduce the rigmarole of diabetes management. One is

a phone app designed to identify and quantify food carbohydrate

content from a photograph. Blood glucose is then measured and

and the device relays the measurement via the app to calculate

correct insulin dose.

The second incorporates a glucose sensor into the surface of

a needle which is left just below the surface of the skin for five to

ten seconds. It then calculates and delivers the precisely required

insulin dose. Both devices have yet to be tested in humans but the

MIT team is confident the principle will work.

www.drugdeliverybusiness.com

Lord Rennard addressed the House

of Lords to explain the value of

diabetes tech on behalf of JDRF

and to ask for greater access to it.

Click the pic to watch a two-minute

summary of his speech..

Across the diabetes sector

many are putting their

shoulders to the wheel

to improve access to and

choice of diabetes tech.

"Let's remind all where

we are nearly at regards

Flash glucose monitoring

or continuous glucose

monitoring (CGM) in NHS

England," said Professor

Partha Kar on Twitter

in mid-February. "First,

we are aiming for it to

be made available for

all people with Type 1

diabetes. Second, there

should be no criterion to

meet; the starting bar is

having Type 1 diabetes.

Third, that there should be

no need to prove the value

of CGM or Flash use. These

points ought to be as per

NICE access to diabetes

technology guidelines,

which are currently under

review. In other words,

access should be just like present

guidance regarding access to glucose

strips. Any local system putting up

barriers to access will be challenged,

clearly and openly in the public

domain with no hesitation at all."

www.twitter.com/parthaskar

Dedicated NHS Diabetes Advice helpline

0345 123 2399

Page 0005

Related Links

Social Sharing Links

Navigation

Related Versions